TransThera Sciences (Nanjing) (HKG:2617) raised HK$161.3 million in net proceeds from its initial public offering in Hong Kong, according to a Friday after-market filing with the Hong Kong bourse.

The clinical-stage biopharmaceutical firm offered 15,281,000 shares priced at HK$13.15 per share, the filing said.

The Hong Kong component of the IPO was 3,419.87 times subscribed, which prompted the company to reallocate shares from the international offering to double the shares offered in the public offering to 3,057,000 shares from 1,528,500 shares initially.

The international offering was 0.97 times subscribed, and the number of shares offered was reduced to 12,224,000 shares following the reallocation.

TransThera Sciences will make its trading debut on the Hong Kong bourse Monday, June 23.